From: A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Medicine costs
Hospitalization costs
Direct costs
pre-PP1M (¥)
8992±3414
25,656±18,756
34,700±18,044
Post-PP1M (¥)
21,961±5492
7179±10,552
27,705±8266
Difference
144%
-72.02%
-20.16%
P
< 0.01